Last reviewed · How we verify
Shingrix (shingrix)
Shingrix (generic name: shingrix) is a Vaccine drug developed by GSK. It is currently FDA-approved for Prevention of herpes zoster (shingles) in adults aged 50 years and older.
Shingrix is a vaccine that targets the envelope glycoprotein E of the varicella zoster virus, which causes herpes zoster and shingles. It is classified as a vaccine antigen and is used to prevent vaccine-preventable diseases, including shingles and herpes zoster.
At a glance
| Generic name | shingrix |
|---|---|
| Sponsor | GSK |
| Drug class | Vaccine |
| Target | Varicella zoster virus |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| Annual revenue | 4300 |
Approved indications
- Prevention of herpes zoster (shingles) in adults aged 50 years and older
Common side effects
- Pain
- Myalgia
- Fatigue
- Headache
- Redness
- Shivering
- Swelling
- Fever
- Gastrointestinal symptoms
- Pain Grade 3
- Myalgia Grade 3
- Fatigue Grade 3
Drug interactions
- Live, attenuated influenza vaccines
- Live vaccines
- Other vaccines
- Immunosuppressive therapies
- Interferon-alpha
- Interferon-gamma
- Corticosteroids
- Azathioprine
- Cyclophosphamide
- Cyclosporine
- Methotrexate
- Sirolimus
Key clinical trials
- Recombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients (PHASE4)
- A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults (PHASE1, PHASE2)
- Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia (PHASE4)
- Addressing Unfunded Vaccines Through a Co-payment Mechanism in Pharmacies (NA)
- Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above (PHASE2)
- Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators (PHASE4)
- Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population (PHASE1, PHASE2)
- Zoster Vaccine to Enhance Protection Against Zoster in Solid-organ Transplantation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Shingrix CI brief — competitive landscape report
- Shingrix updates RSS · CI watch RSS
- GSK portfolio CI
Frequently asked questions about Shingrix
What is Shingrix?
What is Shingrix used for?
Who makes Shingrix?
What is the generic name of Shingrix?
What drug class is Shingrix in?
What development phase is Shingrix in?
What are the side effects of Shingrix?
What is Shingrix's annual revenue?
What does Shingrix target?
Related
- Drug class: All Vaccine drugs
- Target: All drugs targeting Varicella zoster virus
- Manufacturer: GSK — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Prevention of herpes zoster (shingles) in adults aged 50 years and older
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing